Squarepoint’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Squarepoint’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,633	Closed	-$199K	–	3951
2022 Q4	$199K	Buy	+5,633	New	+$677K	﹤0.01%	2792
2021 Q1	–	Sell	-1,846	Closed	-$681K	–	3744
2020 Q4	$681K	Buy	1,846 +1,388	+303%	+$398K	0.01%	1583
2020 Q3	$112K	Buy	+458	New	+$142K	﹤0.01%	2266
2020 Q2	–	Sell	-1,390	Closed	-$284K	–	2588
2020 Q1	$284K	Sell	1,390 -2,784	-67%	-$887K	0.01%	1320
2019 Q4	$1.87M	Buy	4,174 +266	+7%	+$94.4K	0.01%	946
2019 Q3	$1.2M	Sell	3,908 -178	-4%	-$57.8K	0.01%	1099
2019 Q2	$1.3M	Buy	4,086 +2,448	+149%	+$848K	0.01%	1105
2019 Q1	$687K	Buy	1,638 +416	+34%	+$167K	0.01%	1306
2018 Q4	$372K	Buy	1,222 +882	+259%	+$285K	﹤0.01%	1402
2018 Q3	$122K	Buy	+340	New	+$116K	﹤0.01%	1856

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint's EIGR Position: Q1 2023 in Review

Squarepoint sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2023, closing a stake of 5,633 shares — an estimated $199K sold.

Squarepoint first reported a position in EIGR in Q3 2018 and held it in 10 quarters. The position peaked at $1.87M in Q4 2019. 71 funds tracked by Wall St. Rank hold EIGR as of Q1 2023.

Squarepoint reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Squarepoint sold 5,633 Eiger BioPharmaceuticals, Inc. shares in Q1 2023, an estimated $199K.
Squarepoint first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2018 and held it in 10 quarters.
Squarepoint's Eiger BioPharmaceuticals, Inc. position peaked at $1.87M in Q4 2019.
71 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2023.

Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.